H. Lundbeck launched an early-stage study for compound Lu AF76432 for the treatment of schizophrenia and Alzheimer's disease.
A Series A financing round raised $40 million for Accent Therapeutics, which is developing gene regulation technologies targeting messenger RNA in a new scientific field called epitranscriptomics. Bob Copeland, Accent co-founder, president and chief scientific officer, hasn't said what types of cancer targets the company will pursue, but additional funding will be required to bring its first lead candidate into the clinical trial stage.
Scientists from Wageningen University & Research and Teagasc, the Irish authority on agriculture and food development, have developed a biotech potato that, combined with a new pest management strategy, requires minimal fungicide use. The biotech Desiree potato combined with the new pest management approach resulted in a consistent fungicide reduction of 80% to 90%.
A team of researchers from India, Korea and Spain discovered a way to increase biofuel production by 30% by knocking out phosphoinositol 3-kinase, which regulates lipid production in algae.
A round of financing brought in $16 million for cardiac imaging software developer Circle Cardiovascular Imaging. The proceeds will be used for marketing the company's cardiovascular imaging software suite, designed for cardiovascular disease diagnosis, and for further development of software modules for CT, transcatheter aortic valve implantation, 4D flow MRI and mitral and interventional cardiology.
Financing worth $7.2 million was raised by Holland, Mich.-based Genesis Innovation Group for its fund dedicated to medical device, orthopedic technology and other early-stage health care companies, bringing itself closer to its goal of $10 million. Among Genesis' portfolio companies are total knee replacement-focused iMAGEN Orthopedics, replacement shoulder maker Shoulder Innovations and bone growth device maker Magnesium Development.
A round of financing pulled in an undisclosed amount for Canadian medical data company Canary Medical, which makes the Canary Health Implantable Reporting Processor for remote patient monitoring. The proceeds will be used for continued expansion of the company's operations.
Roche Holding and French pharmaceutical firm Pierre Fabre announced an extension to their deal under which a prototype immunohistochemistry assay will be developed by Roche as a companion diagnostic for Pierre's W0101 antibody drug conjugate product candidate for insulin-like growth factor 1 receptor. The extended deal, for which terms were undisclosed, calls for IGF-1R expression to be retrospectively determined in participants of the international Phase I/II clinical study of patients with refractory or relapsed solid tumors.
A Meddevicetracker report predicts the worldwide market for infusion pumps and associated disposables will see a 6.4% compound annual growth rate through 2022, hitting $9.9 billion, because of the increasing aging population and the growing number of chronic disease and associated obesity cases. The market is led by the insulin pump segment, which will see a 9.1% compound annual growth rate throughout the period.
Two clinical studies presented at the World Federation of Hemophilia congress in Glasgow, Scotland, showed that Roche Holding's hemophilia drug Hemlibra substantially decreased bleeding in a wide variety of patients with hemophilia. The drug reduced treated bleeds by 96% in patients with hemophilia A who received no preventive treatment, and it reduced treated bleeds by 68% in patients who received clotting factors.